Investors Have Chance to Take Lead in Avantor, Inc. Securities Fraud Lawsuit
Investors should take heed of a class action lawsuit against Avantor, Inc. (“Avantor” or “the Company”) (NYSE: AVTR) for breaching §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 imposed by the U.S. Securities and Exchange Commission. The Schall Law Firm is reminding investors who acquired the Company’s securities between March 5, 2024, and October 28, 2025, inclusive (the “Class Period”) to make contact with the firm by December 29, 2025.
If shareholders have incurred a loss, they are encouraged to participate. We advise individuals to get in touch with Brian Schall of the Schall Law Firm, whose office is located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. He can be reached at 310-301-3335 for a free consultation. You can also visit the firm’s website at www.schallfirm.com or send an email to [email protected].
It is essential to note that the class has not been certified yet, and until certification takes place, shareholders are not represented by an attorney. However, in the event that no action is taken, investors can still be considered absent class members.
The Complaint filed against the Company alleges that Avantor provided false and misleading information to the market. It was revealed that Avantor was not in as strong a position relative to its rivals as it had indicated to investors. Additionally, the Company was grappling with the adverse effects of heightened competition. Consequently, the Company’s public statements were misleading and inaccurate during the class period. As the market became aware of the truth about Avantor, investors sustained losses.
To recover your losses, consider joining the case. The Schall Law Firm serves investors globally and focuses on securities class action lawsuits and shareholder rights litigation.
It is essential to recognize that this press release may be deemed Attorney Advertising in specific jurisdictions pursuant to applicable laws and ethical regulations.